American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.
Matthew M Harkenrider, Alec M Block, Kaled M Alektiar...
https://pubmed.ncbi.nlm.nih.gov/27260082/Actively Recruiting
Led by University of Utah · Updated on 2025-12-12
188
Participants Needed
5
Research Sites
152 weeks
Total Duration
Researchers are evaluating short course vaginal cuff brachytherapy compared with the standard care of vaginal cuff brachytherapy in participants with stage I-II endometrial cancer. This phase III randomized trial aims to see how well the shorter treatment works and to assess its impact on patient quality of life and financial burden. The study was expanded after initial recruitment to include additional participants and monitor financial toxicity alongside quality of life outcomes. The trial compares two treatment groups one group receives short course vaginal cuff brachytherapy with 2 fractions spaced 1 week apart, while the other group receives the standard of care with 3 to 5 fractions over no more than 3 weeks. Both treatments involve placing radioactive material directly into or near the upper vagina to target cancer cells after surgery. Participants are closely monitored during and after treatment, with assessments of quality of life, treatment-related symptoms, diet, and activity levels. Financial toxicity and costs related to procedures are also evaluated. Outcome measures include changes in quality of life and patient-reported financial impact at one month post-treatment. The study continues until 2029, with ongoing recruitment and follow-up.
CONDITIONS
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
R
Rachel Kingsford
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Utah
Lead Sponsor
Huntsman Cancer Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Short Course Vaginal Cuff Brachytherapy | Standard Course Vaginal Cuff Brachytherapy |
|---|---|---|
| What it is | A condensed schedule of adjuvant vaginal cuff brachytherapy delivered after hysterectomy for early-stage endometrial cancer. | Conventional, multi-session adjuvant vaginal cuff brachytherapy, following standard clinical protocols post-hysterectomy. |
| Role in trial | Participants are randomly assigned to receive the experimental reduced-duration brachytherapy. | Participants are randomly assigned to the control arm, receiving standard adjuvant brachytherapy as per routine practice. |
| Primary use | Adjuvant radiation therapy aiming to prevent vaginal recurrence after removal of early-stage endometrial cancer. | Adjuvant radiation therapy designed to reduce vaginal relapse risk following definitive surgery for early-stage endometrial cancer. |
| How it is given or performed | Delivered as a reduced number of high-dose-rate treatments to the vaginal cuff using a brachytherapy applicator, after hysterectomy. | Administered as multiple high-dose-rate sessions (typically several fractions) using a vaginal applicator, consistent with standard care. |
| Evidence status | Evidence for short-course schedules is emerging and under evaluation; registry and limited published data indicate potential feasibility, but large-scale effectiveness and safety data remain limited. | Conventional adjuvant vaginal cuff brachytherapy is supported by high-quality guidelines and large studies as an effective method to reduce vaginal recurrence risk in early-stage endometrial cancer. |
| Important limitations | Long-term safety and effectiveness are not yet fully established; early studies suggest feasibility, but comprehensive outcomes and late toxicity data are still being collected. | While effective, conventional schedules require multiple clinic visits and may increase short-term vaginal and pelvic symptoms; patient-reported financial toxicity and quality-of-life impact have been increasingly recognized. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 weeks
Participants receive either short course vaginal cuff brachytherapy (2 fractions spaced 1 week apart) or standard vaginal cuff brachytherapy (3-5 fractions over no more than 3 weeks).
Multiple treatment visits depending on assigned brachytherapy schedule
Duration - Up to 6 months
Participants are monitored for quality of life, treatment-related symptoms, and financial toxicity up to 6 months after treatment.
1 visit at 1 month post-treatment and 1 visit approximately 6 months after treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew M Harkenrider, Alec M Block, Kaled M Alektiar...
https://pubmed.ncbi.nlm.nih.gov/27260082/Kim Cocks, Madeleine T King, Galina Velikova...
https://pubmed.ncbi.nlm.nih.gov/18599286/Justine M Briët, Harry Hollema, Nathalie Reesink...
https://pubmed.ncbi.nlm.nih.gov/15721428/Eunkyung Lee, Jianbin Zhu, Julia Velazquez...
https://pubmed.ncbi.nlm.nih.gov/33158797/Alfred I Neugut, Milayna Subar, Elizabeth Ty Wilde...
https://pubmed.ncbi.nlm.nih.gov/21606426/Christopher M Lee, Aniko Szabo, Dennis C Shrieve...
https://pubmed.ncbi.nlm.nih.gov/17849468/Christopher M Lee, Aniko Szabo, Dennis C Shrieve...
https://pubmed.ncbi.nlm.nih.gov/16434629/Anke Smits, Alberto Lopes, Nagindra Das...
https://pubmed.ncbi.nlm.nih.gov/26441008/R A Nout, V T H B M Smit, H Putter...
https://pubmed.ncbi.nlm.nih.gov/20206777/J Aalders, V Abeler, P Kolstad...
https://pubmed.ncbi.nlm.nih.gov/6999399/University of Utah
Lead Sponsor
Huntsman Cancer Institute
Collaborating Sponsor